Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Potent, selective human beta3-adrenoceptor antagonists discovered at Merck & Co.

Sep. 7, 1999

Celera Genomics and Gemini Research establish research collaboration

Sep. 7, 1999

SkyePharma acquires nanoparticle technology

Sep. 7, 1999

PDL granted new European patent covering humanized monoclonal antibodies

Sep. 7, 1999

3-Dimensional awarded two research grants from NIH

Sep. 6, 1999

Ligand and Parke-Davis establish research collaboration

Sep. 6, 1999

Licensing opportunity from NIH: drug delivery system for water-insoluble drugs

Sep. 6, 1999

Orally bioavailable, ETB receptor-selective antagonists designed by Abbott

Sep. 3, 1999

Millennium extends CNS collaboration with Wyeth-Ayerst

Sep. 2, 1999

Repligen receives SBIR grants to support discovery of novel active compounds

Aug. 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...